Researchers have discovered a new treatment for asthma and chronic obstructive pulmonary disease (COPD) that could transform patient care worldwide. A recent study published in The Lancet highlights benralizumab, an anti-inflammatory drug developed by AstraZeneca (AZN, Financial), as a more effective alternative to current steroid treatments. This injectable medication can rapidly reduce eosinophils, cells that contribute to lung inflammation, within 24 hours, potentially lowering the frequency of treatment needs.
The study, led by King's College London, involved 158 patients and demonstrated significant improvements in respiratory symptoms and reduced treatment failures compared to steroid use. Benralizumab's advantages include fewer side effects than steroids, which can increase the risk of diabetes and osteoporosis.
Experts emphasize the urgent need for more effective therapies for COPD, the third leading cause of death globally. This breakthrough marks the first new treatment for asthma and COPD in 50 years, underscoring the need for increased funding in lung health research.
